Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company that was established to discover, develop and commercialize innovative treatments for infectious diseases. Within the anti-infective market, we are currently concentrating on the development of antivirals for the treatment of chronic hepatitis C viral infection, or HCV. Recently, we have been developing our three lead clinical-stage drug candidates for the treatment of HCV, including sovaprevir and ACH-3102, each currently in phase II clinical development, and ACH-2684, currently in phase I clinical development. In the near term, we intend to focus our efforts on (i) initiating clinical development of a combination regimen including sovaprevir and ACH-3102, with and without ribavirin, (ii) continuing our study of ACH-3102 plus ribavirin and (iii) exploring potential development of our drug candidates with other drug developers under cooperative or other study arrangements. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.64 |
| Quarterly EPS Est: | -0.15 |
| PEG Ratio: | -2.71 |
|
Mean Recommendation: View Summary / View All |
1.33 |
Data is provided by Zacks Investment Research

